THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) lobbying for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$1,370,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

KRISTINA KAYE WEGER New on this filing

Previously held: Health Policy and Communications Director, U.S. Rep. Blaine Luetkemeyer (MO); Intern, U.S. Sen. Roy Blunt (MO)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 12

S 864
HELP Copays Act
HR 247
Health Care Affordability Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 2296
National Defense Authorization Act for Fiscal Year 2026
S 1542
DRUG Act
HR 2214
DRUG Act
HR 5378
Lower Costs, More Transparency Act
S 1339
Pharmacy Benefit Manager Reform Act
S 526
Pharmacy Benefit Manager Transparency Act of 2025
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act

Lobbying activity 5

Medicare/Medicaid

Issues related to prior authorization.

Health Issues

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.

Defense

H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.

Pharmacy

S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.

Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.